Monica M. Yang

Monica M. Yang

Auto-generated profile, based on publicly available information

Monica M. Yang

Division of Rheumatology, University of California San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDParakkal Deepak
Parakkal Deepak
WKWooseob Kim
Wooseob Kim
MPMichael A. Paley
Michael A. Paley
MYMonica Yang
Monica Yang
ACAlexander B. Carvidi
Alexander B. Carvidi
AKAlfred Kim
Alfred Kim
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine ... Visual Effect of Immunosuppression on Immunogenicity of mRNA SARS-CoV-2 Vaccines. Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients ma... Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides ...

2 July 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
MBMarie Binvignat
Marie Binvignat
BMBrenda Y. Miao
Brenda Y. Miao
CWCamilla Wibrand
Camilla Wibrand
MYMonica M. Yang
Monica M. Yang
DRDmitry Rychkov
Dmitry Rychkov
MSMarina Sirota
Marina Sirota
Rheumatoid arthritis (RA) management leans toward achieving remission or low disease activity. In this study, we conducted single-cell RNA sequencing (scRNA-Seq) of peripheral blood mononuclear cells (PBMCs) from 36 individuals (18 patients with RA and 18 matched controls, accounting for age, sex, race, and ethnicity), to identify disease-relevant cell subsets and cell type–specific signatures associated with disease activity. Our analysis revealed 18 distinct PBMC subsets, including an IFN-induced transmembrane 3–overexpressing (IFITM3-overexpressing) IFN-activated monocyte subset. We observed an increase in CD4 + T effector memory cells in patients with moderate-high disease activity (DAS28-CRP ≥ 3.2) and a decrease in nonclassical monocytes in patients with low disease activity or remission (DAS28-CRP < 3.2). Pseudobulk analysis by cell type identified 168 differentially expressed genes between RA and matched controls, with a downregulation of proinflammatory genes in the γδ T cell subset, alteration of genes associated with RA predisposition in the IFN-activated subset, and nonclassical monocytes. Additionally, we identified a gene signature associated with moderate-high disease activity, characterized by upregulation of proinflammatory genes such as TNF , JUN , EGR1 , IFIT2 , MAFB , and G0S2 and downregulation of genes including HLA-DQB1 , HLA-DRB5 , and TNFSF13B . Notably, cell-cell communication analysis revealed an upregulation of signaling pathways, including VISTA, in both moderate-high and remission-low disease activity contexts. Our findings provide valuable insights into the systemic cellular and molecular mechanisms underlying RA disease activity.

7 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
PDParakkal Deepak
Parakkal Deepak
WKWooseob Kim
Wooseob Kim
MPMichael A. Paley
Michael A. Paley
MYMonica Yang
Monica Yang
ACAlexander B. Carvidi
Alexander B. Carvidi
BNBilly Nix
Billy Nix
Background: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity in CID patients on immunosuppression is not well established. Therefore, determining the effectiveness of SARS-CoV-2 vaccines in the setting of immunosuppression is essential to risk-stratify CID patients with impaired protection and provide clinical guidance regarding medication management. Methods: We conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 spike (S) IgG + binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination. Results: Compared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization. Conclusions: CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.

1 May 2021 in Teaching and Learning in Medicine
Verified
Journal Article
Closed access
MYMonica M. Yang
Monica M. Yang
BGBlair P. Golden
Blair P. Golden
KCKenzie A. Cameron
Kenzie A. Cameron
LGLauren Gard
Lauren Gard
JBJennifer A. Bierman
Jennifer A. Bierman
BHBruce L. Henschen
Bruce L. Henschen
Classroom studies of peer-led teaching and mentoring report benefits for students both as teachers and learners. Such benefits include both improved content mastery and personal and professional de...

25 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
MYMonica M. Yang
Monica M. Yang
SLSeoyeon Lee
Seoyeon Lee
JNJessica Neely
Jessica Neely
MHMonique Hinchcliff
Monique Hinchcliff
PWPaul J. Wolters
Paul J. Wolters
MSMarina Sirota
Marina Sirota
Aging and cellular senescence are increasingly recognized as key contributors to pulmonary fibrosis. However, our understanding in the context of scleroderma-associated interstitial lung disease (SSc-ILD) is limited. To investigate, we leveraged previously established lung aging- and cell-specific senescence signatures to determine their presence and potential relevance to SSc-ILD. We performed a gene expression meta-analysis of lung tissues from 38 SSc-ILD and 18 healthy controls and found that markers (GDF15, COMP, and CDKN2A) and pathways (p53) of senescence were significantly increased in SSc-ILD. When probing the established aging and cellular senescence signatures, we found that epithelial and fibroblast senescence signatures had a 3.6- and 3.7-fold enrichment, respectively, in the lung tissue of SSc-ILD and that lung aging genes (CDKN2A, FRZB, PDE1A, and NAPI12) were increased in SSc-ILD. These signatures were also enriched in SSc skin and associated with degree of skin involvement (limited vs. diffuse cutaneous). To further support these findings, we examined telomere length (TL), a surrogate for aging, in the lung tissue and found that, independent of age, SSc-ILD had significantly shorter telomeres than controls in type II alveolar cells in the lung. TL in SSc-ILD was comparable to idiopathic pulmonary fibrosis, a disease of known aberrant aging. Taken together, this study provides novel insight into the possible mechanistic effects of accelerated aging and aberrant cellular senescence in SSc-ILD pathogenesis.

13 March 2023 in Arthritis Care & Research
Verified
Journal Article
Closed access
MYMonica Yang
Monica Yang
VGVivien Goh
Vivien Goh
JLJungwha Lee
Jungwha Lee
MEMonica Espinoza
Monica Espinoza
YYYiwei Yuan
Yiwei Yuan
MHMonique Hinchcliff
Monique Hinchcliff